The Vascular Screening Devices Market size is estimated at USD 1.74 billion in 2024, and is expected to reach USD 2.25 billion by 2029, growing at a CAGR of 5.35% during the forecast period (2024-2029).
During the COVID-19 pandemic, it was known that the lung was the primary organ to be affected; however, recent research indicates that SARS-CoV-2 infection can result in vascular illness also. According to the study published in JACC: Cardiovascular Imaging Journal in September 2021, in the early stages of the pandemic, there was a considerable decrease in cardiovascular testing in the United States, with significant variation between locations.
Furthermore, numerous studies revealed that persons with heart illnesses were particularly vulnerable to COVID-19, which decreased patient traffic in hospitals and diagnostic centers. According to the study published by the National Center for Biotechnology Information (NCBI) in May 2021, during the COVID-19 pandemic, cardiac procedural activity in England decreased dramatically, with a deficit of approximately 45,000 procedures, with no increase in the risk of mortality for most cardiac procedures performed during the pandemic. Thus, the decline in surgical procedures during the pandemic significantly impacted the market growth.
The growing burden of vascular diseases and the rising geriatric population are the key factors in the vascular screening devices market. As per the 2020 updates by the World Health Organization (WHO), ischemic heart disease was responsible for 16% of the world's total deaths. As per the article published in May 2021 in the Journal of Circulation Research, there were around 6,859,623 heart failure patients in the United States in 2020, reflecting 2.1% of the population. Furthermore, in 2020, the prevalence of heart failure in the United States and Canada was 1.5% and 1.9%, respectively. Thus, the growing burden of cardiovascular diseases is expected to boost market growth during the forecast period.
Furthermore, chronic diseases are more prevalent in the geriatric population and will likely boost market growth over the forecast period. For instance, the WHO's data published in October 2021 reported that the pace of population aging is much faster than in the past, and by 2030, 1 in 6 people worldwide will be aged 60 years or over. At this time, the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion by 2030. This growth in the aging population will ultimately drive the demand for the vascular screening device market, as vascular diseases are more prone in the geriatric population.
However, reimbursement issues may restrain market growth over the forecast period.
The vascular screening devices market is moderately competitive and consists of several major players. Some of the companies that are operating in the vascular screening devices market are Fukuda, Unetixs Vascular Inc., Collaborative Care Diagnostics LLC (Biomedix), CorVascular Diagnostics LLC, Koven Technology Inc., D.E. Hokanson Inc., enverdis GmbH, OMRON HEALTHCARE Co. Ltd, Viasonix, and Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook